Congratulations to Meg Jardine & Kevan Polkinghorne for their trials, RESOLVE and PISCES.
We are excited to announce NHMRC funding success for the RESOLVE and PISCES trials. Both trials have received a Project Grant which will allow them to commence in early 2017.
Haemodialysis (HD) is a complex yet vital life-sustaining service for those living with chronic kidney disease (CKD). Unfortunately, dialysate sodium concentrations have recently drawn attention due to their potential impact on the ongoing excess of cardiovascular morbidity among people receiving HD. The lack of evidence is resulting in a variation of practice in Australia (as well as globally) and the RESOLVE trial seeks to provide some definitive answers.
Led by A/Prof Meg Jardine, RESOLVE seeks to test whether lower (137mmol/L) versus higher (140mmol/L) dialysate sodium levels have an effect on cardiovascular outcomes in dialysis patients. The Australasian Kidney Trials Network will be coordinating the Australian arm of the study and A/Prof Meg Jardine and her team at the George Institute will be leading the global arm.
Congratulations to her and the team on this great success.
For click here to stay up to date on the RESOLVE trial.
PISCES: Protection against Incidences of Serious Cardiovascular Events Study
Mortality from Cardiovascular Disease (CVD) is at least forty times greater in end-stage kidney disease patients compared to the general population. We are in need of interventions that target the underlying mechanisms of CVD which include inflammation and oxidative stress. PISCES proposes to use high-dose long-chain omega-3 polyunsaturated essential fatty acids found in fish oil. Despite previous trials indicating a potential benefit of using fish oil, there remains uncertainty in supplementing Haemodialysis (HD) patients and this trials seeks to provide some answers.
We congratulate A/Prof Kevan Polinghorne on his Project Grant success and the Australasian Kidney Trials looks forward to coordinating the Australian arm.
For click here to stay up to date on the PISCES trial.